Hiroyuki  Fukuda

Dr. Hiroyuki Fukuda


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2020 in Cancers
Verified
Journal Article
Open access
PDF file
MCMakoto Chuma
Makoto Chuma
HUHaruki Uojima
Haruki Uojima
KNKazushi Numata
Kazushi Numata
HHHisashi Hidaka
Hisashi Hidaka
HTHidenori Toyoda
Hidenori Toyoda
Shin MaedaShin Maeda
Shin Maeda
Predictive biomarkers of the response of hepatocellular carcinoma (HCC) to Lenvatinib therapy have not yet been clarified. The aim of this study was to identify clinically significant biomarkers of response to Lenvatinib therapy, to target strategies against HCC. Levels of circulating angiogenic factors (CAFs) were analyzed in blood samples collected at baseline and after introducing lenvatinib, from 74 Child-Pugh class A HCC patients who received lenvatinib. As CAF biomarkers, serum vascular endothelial growth factor (VEGF), fibroblast growth factor 19 (FGF19), FGF23, and angiopoietin-2 (Ang-2) were measured using enzyme-linked immunosorbent assays. Results: Significantly increased FGF19 (FGF19-i) levels and decreased Ang-2 (Ang-2-d) levels were seen in Lenvatinib responders as compared to non-responders (ratio of FGF19 level at 4 weeks/baseline in responders vs. non-responders: 2.09 vs. 1.32, respectively, p = 0.0004; ratio of Ang-2 level at four weeks/baseline: 0.584 vs. 0.810, respectively, p = 0.0002). Changes in FGF23 and VEGF levels at four weeks versus baseline, however, were not significantly different in responders versus non-responders. In multivariate analysis, the combination of serum FGF19-i and Ang-2-d was the most independent predictive factor for Lenvatinib response (Odds ratio, 9.143; p = 0.0012). Furthermore, this combination biomarker showed the greatest independent association with progression-free survival (Hazard ratio, 0.171; p = 0.0240). Early changes in circulating FGF19 and Ang-2 levels might be useful for predicting clinical response and progression-free survival in HCC patients on Lenvatinib therapy.

1 August 2014 in Radiology
Verified
Journal Article
Closed access
HFHiroyuki Fukuda
Hiroyuki Fukuda
KNKazushi Numata
Kazushi Numata
YSYu Shimoyama
Yu Shimoyama
TITomohiro Ishii
Tomohiro Ishii
ANAkito Nozaki
Akito Nozaki
KTKatsuaki Tanaka
Katsuaki Tanaka
Combined sorafenib and radiofrequency ablation (RFA) is superior to standard RFA alone when larger coagulation areas are required. PurposeTo retrospectively compare radiofrequency ablation (RFA) combined with the multikinase inhibitor sorafenib (hereafter, sorafenib-RFA) and RFA alone in the treatment of hepatocellular carcinoma (HCC).Materials and MethodsInstitutional review board approval and informed consent were obtained. Between January 2007 and December 2011, 16 patients (mean age, 72.8 years; age range 52–84 years; 10 men, six women) with HCC tumors less than 3 cm in diameter were included in the sorafenib-RFA group, and 136 patients (mean age, 72.1 years; age range, 51–86 years; 92 men, 44 women) with HCC tumors less than 3 cm in diameter were included in the RFA alone (control) group. Mean diameters of the greatest long-axis dimensions of HCC were 22.8 mm ± 4.6 (standard deviation) in the sorafenib-RFA group and 18.1 mm ± 4.4 in the control group. RFA was performed immediately after the 7-day administration of sorafenib. Propensity score matching analysis was used to adjust for potential biases.ResultsFifteen of the 16 patie...

1 August 2011 in Ultrasound in Medicine & Biology
Verified
Journal Article
Closed access
HFHiroyuki Fukuda
Hiroyuki Fukuda
RIRyu Ito
Ryu Ito
MOMasao Ohto
Masao Ohto
ASAkio Sakamoto
Akio Sakamoto
EKEii Karasawa
Eii Karasawa
ZWZhi-Biao Wanga
Zhi-Biao Wanga


1 December 2011 in European Journal of Radiology
Verified
Journal Article
Closed access
HFHiroyuki Fukuda
Hiroyuki Fukuda
KNKazushi Numata
Kazushi Numata
ANAkito Nozaki
Akito Nozaki
MKMasaaki Kondo
Masaaki Kondo
MMManabu Morimoto
Manabu Morimoto
ZWZhi-Biao Wang
Zhi-Biao Wang

31 December 2011 in European Journal of Radiology
Verified
Journal Article
Closed access
HFHiroyuki Fukuda
Hiroyuki Fukuda
KNKazushi Numata
Kazushi Numata
ANAkito Nozaki
Akito Nozaki
MMManabu Morimoto
Manabu Morimoto
MKMasaaki Kondo
Masaaki Kondo
ZWZhi-Biao Wang
Zhi-Biao Wang